Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

Shares of Denmark’s Novo Nordisk rose 3.5% to 613.30 kroner this morning, after the company reported better-than-expected net ...

For years, obesity was often seen as a result of poor lifestyle choices. However, experts now suggest that biological factors ...

barely moving the needle against Zepbound. With Wegovy now playing catch-up and CagriSema failing to shake up the game, Novo is staring down a serious challenge from Lilly, which is running away ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Wegovy and Zepbound tipped to fuel $20B boom ... questions remain about how Novo's latest numbers can move the needle in a competitive market. The company's stock price decline of 4% on Friday ...

GPS systems around the world are adjusting to a new model tracking Earth's magnetic north pole, the point that attracts the needle of a compass ... Newser ・Ozempic, Wegovy Have 'Eye-Opening ...

This class of drugs, which include Wegovy, Mounjaro and Zepbound ... Most GLP-1 agonists are administered via injection, using a needle and syringe to deliver the medication into the fatty ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...